Nivolumab-induced polyarthritis.
作者信息
Kodama Shoko, Kurose Koji, Mukai Tomoyuki, Morita Yoshitaka
机构信息
Department of Rheumatology, Kawasaki Medical School, Kurashiki, Japan.
Department of Respiratory Medicine, Kawasaki Medical School, Kurashiki, Japan.
出版信息
BMJ Case Rep. 2017 Dec 2;2017:bcr-2017-223387. doi: 10.1136/bcr-2017-223387.
Abstract
摘要
相似文献
1
Nivolumab-induced polyarthritis.纳武单抗诱导的多关节炎。
BMJ Case Rep. 2017 Dec 2;2017:bcr-2017-223387. doi: 10.1136/bcr-2017-223387.
2
Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.一名非鳞状转移性非小细胞肺癌患者对纳武单抗的持久反应及免疫相关不良事件
J Thorac Oncol. 2017 May;12(5):e51-e55. doi: 10.1016/j.jtho.2016.12.027.
3
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.纳武利尤单抗相关的间质性肺病分析：两项复发或晚期非小细胞肺癌患者的 II 期研究。
Lung Cancer. 2017 Feb;104:111-118. doi: 10.1016/j.lungcan.2016.12.016. Epub 2016 Dec 21.
4
Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy.诱导性炎症的后果：纳武单抗治疗引起的急性主动脉周炎
BMJ Case Rep. 2017 Sep 23;2017:bcr-2017-221852. doi: 10.1136/bcr-2017-221852.
5
Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.一例转移性非小细胞肺癌患者中出现的晚期发生的nivolumab诱导的隐源性机化性肺炎，酷似肺部进展。
Eur J Cancer. 2017 Nov;85:155-157. doi: 10.1016/j.ejca.2017.07.049. Epub 2017 Sep 13.
6
Association of Serum Anti-GAD Antibody and HLA Haplotypes with Type 1 Diabetes Mellitus Triggered by Nivolumab in Patients with Non-Small Cell Lung Cancer.非小细胞肺癌患者中血清抗谷氨酸脱羧酶抗体及HLA单倍型与纳武利尤单抗引发的1型糖尿病的关联
J Thorac Oncol. 2017 May;12(5):e41-e43. doi: 10.1016/j.jtho.2016.12.015. Epub 2016 Dec 23.
7
Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab.接受纳武利尤单抗治疗的晚期非小细胞肺癌患者早期进展和 3-4 级毒性相关的临床因素。
PLoS One. 2018 Apr 23;13(4):e0195945. doi: 10.1371/journal.pone.0195945. eCollection 2018.
8
Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.纳武利尤单抗在既往治疗的鳞状或非鳞状非小细胞肺癌中的疗效和安全性的暴露-反应分析。
Clin Cancer Res. 2017 Sep 15;23(18):5394-5405. doi: 10.1158/1078-0432.CCR-16-2842.
9
Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.肺组织损伤作为非小细胞肺癌中对纳武单抗的一种非典型反应。
Am J Respir Crit Care Med. 2017 Nov 15;196(10):1349-1350. doi: 10.1164/rccm.201705-0875IM.
10
FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.18F-氟代脱氧葡萄糖正电子发射断层扫描在评估复发非小细胞肺癌患者对纳武单抗的反应中的应用
World J Surg Oncol. 2016 Sep 5;14(1):238. doi: 10.1186/s12957-016-0998-y.
引用本文的文献
1
Immunotherapy-Induced Eosinophilic Tracheitis.免疫疗法诱导的嗜酸性粒细胞性气管炎炎
Cureus. 2022 Apr 13;14(4):e24130. doi: 10.7759/cureus.24130. eCollection 2022 Apr.
2
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.EULAR 针对癌症免疫治疗中使用检查点抑制剂引起的风湿免疫相关不良事件的诊断和管理的考虑要点。
Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23.
3
Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.与检查点抑制剂治疗相关的各种风湿性疾病的频率和分布。
Rheumatology (Oxford). 2019 Dec 1;58(Suppl 7):vii40-vii48. doi: 10.1093/rheumatology/kez297.
4
Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Should Be Treated with Low-dose Prednisolone During Pembrolizumab Therapy.在帕博利珠单抗治疗期间，副肿瘤性缓解性血清阴性对称性滑膜炎伴凹陷性水肿综合征应采用小剂量泼尼松龙治疗。
Intern Med. 2020 Feb 15;59(4):597-598. doi: 10.2169/internalmedicine.3902-19. Epub 2019 Oct 31.
本文引用的文献
1
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?免疫检查点与风湿性疾病：癌症免疫疗法能给我们带来什么启示？
Nat Rev Rheumatol. 2016 Oct;12(10):593-604. doi: 10.1038/nrrheum.2016.131. Epub 2016 Aug 19.
Zotero 插件